We explore CAR T-cell therapy challenges, regulatory approvals, market growth, pricing models, and a...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreNICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...
Read moreIntroduction The European landscape has seen both approvals and withdrawals of cell and gene therapi...
Read moreWe look at whether payers are willing to pay for innovative gene therapies & CAR-Ts and the impact o...
Read moreOur Market Access Analysts discuss the proposed changes to CAR-T reimbursement in the US and conside...
Read morePRIME medicines include CAR T-cell therapies, one-time potentially curative gene therapies, rare can...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read more